查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1198195

去肾神经设备市场——增长、趋势和预测 (2023-2028)

Renal Denervation Devices Market - Growth, Trends, and Forecast (2023 - 2028)
出版日期: | 出版商: Mordor Intelligence | 英文 110 Pages | 商品交期: 2-3个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

在预测期内，肾臟去神经设备市场预计将以 36.89% 的复合年增长率增长。

主要亮点

  • COVID-19 大流行显着减少了医院和医疗保健服务，从而影响了肾臟去神经设备市场。 在 COVID-19 流行期间，许多医疗设备製造商由于缺乏资源和资金而推迟或延迟设备发布，这对去肾神经设备市场产生了负面影响。 然而，儘管存在这些挫折，大流行期间高血压和大量饮酒的上升可能有助于市场在短期内復苏。 例如，根据国家酒精滥用和酒精中毒研究所的数据，2020 年 1 月至 2020 年 8 月期间，美国 15 个州的酒精销售量同比增长 4%，增加了患高血压和去肾神经装置的风险. 可能会刺激使用 因此，由于产品销量增加、新产品发布以及与高血压相关的健康问题增加等因素，预计未来几年所研究的市场将出现增长。
  • 高血压患病率上升和治疗的长期影响是推动去肾神经设备市场增长的主要因素。 近年来，高血压的患病率明显上升。 根据世界卫生组织 2021 年 8 月的更新，全球约有 12.8 亿 30-79 岁的人受到高血压的影响。 预计在预测期内，高血压病例数量的增加将产生对去肾神经设备的需求。 高血压患病率上升的主要原因是人口老龄化、高钠低钾摄入、肥胖增加、低收入和中等收入国家饮酒量增加、体力活动减少、饮食均衡等。在。
  • 此外，儿童和成人肥胖等其他慢性病患病率上升也将在整个预测期内推动去肾神经设备市场的增长。 据世界卫生组织统计，到 2021 年，将有超过 3900 万五岁以下儿童超重。 肥胖人群的高瘦素水平可诱导下丘脑血管增生，从而导致高血压，因此这种情况可能会推高对肾神经去神经治疗的需求。 此外，增加经常饮酒会导致高血压，因为酒精会刺激肾上腺释放肾上腺素，从而导致心率、心输出量和收缩压增加，这将进一步推动市场的增长。
  • 此外，与去肾神经设备相关的临床研究和研发的增加以及去肾设备的长期效益预计将推动市场增长。 例如，根据 2022 年 4 月发表在《自然》杂誌上的一篇论文，泰国 80% 以上的顽固性高血压患者经历了肾神经去神经支配的结果，这些结果在长期随访中得以维持，没有干预相关的副作用。据说它已完成。
  • 因此，由于高血压患病率上升以及肾去神经设备提供的长期益处，预计所研究的市场在预测期内会出现增长。 然而，预计在预测期内，肾去神经设备的严格审批程序、报销制度和痛苦的程序将抑制市场增长。

去肾神经设备的市场趋势

基于超声的细分市场预计在预测期内增长最快

基于超声的肾去神经支配装置是一种微创手术，它使用超声消融肾动脉壁中的神经。 它可以阻止神经衝动传入和传出肾臟并降低血压。 由于高血压患病率上升和对基于超声的去肾神经设备的需求增加等因素，基于超声的去肾神经设备有望显示市场增长。 例如，根据世界卫生组织 2022 年 6 月的更新，估计印度至少有四分之一的成年人患有高血压，其中只有约 12% 的人血压得到控制。 这种高血压与高胆固醇水平有关，其发病率的增加可能会加强对基于超声的去肾神经设备的产品需求。

此外，预计在预测期内，对超声肾去神经支配设备的研究越来越多，将推动市场增长。 例如，根据 2021 年 10 月发表在 PubMed 上的一篇论文，超声 In REQUIRE 试验旨在评估日本和韩国顽固性高血压患者接受去肾神经术的降压效果。 此类试验的有利结果可能会导致新的治疗选择，并在预测期内提高该部门的增长率。

创新产品发布和研究合作是主要市场参与者在该领域采取的一些举措，以提高其在全球市场的影响力。 例如，2020 年 12 月，ReCor Medical Inc. 因其革命性的 Paradise 超声肾去神经系统获得了美国 FDA 的突破性设备称号，该系统旨在利用超声波能量消融肾神经。。 因此，由于高血压患病率上升、与基于超声的肾去神经设备相关的研究活动增加以及产品批准的增加，预计研究部门在预测期内将出现市场增长。

预测期内，欧洲去肾神经设备市场有望显着增长

由于高血压患病率上升、技术进步不断增加以及治疗的长期影响等因素，欧洲的去肾神经设备市场可能会出现显着增长。 例如，根据健康改善和差异办公室的统计数据，2021 年英格兰的高血压患病率为 845.76 万人。 此外，根据2021年在意大利进行的一项调查，73.6%的参与者表示他们知道自己的血压状况，42.3%的人被诊断为高血压，41.4%的人正在服用降压药。我回答是。 此外，男性自报高血压的患病率高于女性。 因此，高血压发病率的增加已成为推动该地区增长的关键因素之一。

此外，增加研发活动以开发高效设备也是推动市场增长的主要因素。 该地区产品发布数量的增加也将有助于市场增长。 例如，2021 年 10 月，ReCor Medical Inc. 将在欧洲推出超声波去肾神经系统，该系统可能会在德国用于治疗未控制的高血压。 因此，由于高血压患病率上升和肾去神经设备产品批准的增加，预计欧洲在预测期内将出现增长。

去肾神经设备市场竞争对手分析

由于几家主要参与者的存在，市场正在整合。 各大公司纷纷采取研发、併购、产品发布等多种策略来巩固市场地位。

市场参与者包括 Abbott、Ablative Solutions、Boston Scientific Corporation、CardioSonic、Kona Medical、Medtronic PLC、Mercator MedSystems、ReCor Medical 和 Simple Surgical。

其他好处

  • Excel 格式的市场预测 (ME) 表
  • 3 个月的分析师支持

内容

第1章介绍

  • 研究假设和市场定义
  • 调查范围

第2章研究方法论

第 3 章执行摘要

第四章市场动态

  • 市场概览
  • 市场驱动因素
    • 高血压患病率上升
    • 治疗的长期效果
  • 市场製约因素
    • 痛苦的治疗
    • 去肾神经设备的严格审批流程和报销制度
  • 波特的五力分析
    • 新进入者的威胁
    • 消费者的议价能力
    • 供应商的议价能力
    • 替代品的威胁
    • 竞争公司之间的敌对关係

第 5 章市场细分（基于价值的市场规模：100 万美元）

  • 按技术
    • 基于无线电波
    • 基于超声
    • 微输液
  • 按地区
    • 北美
      • 美国
      • 加拿大
      • 墨西哥
    • 欧洲
      • 德国
      • 英国
      • 法国
      • 意大利
      • 西班牙
      • 其他欧洲地区
    • 亚太地区
      • 中国
      • 日本
      • 印度
      • 澳大利亚
      • 韩国
      • 其他亚太地区
    • 世界其他地区

第6章竞争格局

  • 公司简介
    • Medtronic PLC
    • Abbott Laboratories（St. Jude Medical Inc.）
    • Otsuka Holdings Co. Ltd（ReCor Medical Inc.）
    • Ablative Solutions Inc.
    • Mercator MedSystems
    • Terumo Corporation
    • Symple Surgical
    • Boston Scientific Corporation
    • SoniVie
    • Recor Medical Inc.

第7章 市场机会与今后动向

简介目录
Product Code: 57103

The renal denervation devices market is expected to register a CAGR of 36.89% during the forecast period.

Key Highlights

  • The outbreak of the COVID-19 pandemic impacted the renal denervation devices market as hospitals and healthcare services significantly reduced due to social distancing measures taken by countries across the world. During the COVID-19 outbreak, many medical device manufacturers either delayed or postponed the launch of their devices due to resource and fund crunch, negatively impacting the renal denervation devices market. However, despite these setbacks, rising levels of hypertension coupled with high alcohol consumption during the pandemic may contribute to the market recovery over the foreseeable future. For instance, according to the National Institute on Alcohol Abuse and Alcoholism, the quantity of alcohol sold in 15 US states rose by 4% from January to August 2020 as compared to a year earlier, which could increase the risk of hypertension and stimulate the use of renal denervation devices. Hence, the studied market is anticipated to witness growth in the coming years owing to factors such as a rise in product sales, new product launches, and an increase in hypertension-related health issues.
  • Major factors responsible for the growth of the renal denervation devices market include the rising prevalence of hypertension and the long-lasting effect of the procedure. The prevalence of hypertension has been observing a significant rise over the past few years. According to the August 2021 update from the WHO, around 1.28 billion people aged between 30 and 79 years are affected by hypertension globally. An increase in the number of cases of hypertension is expected to create demand for renal denervation devices during the forecast period. Some major reasons for an increase in the prevalence of hypertension are the increasing geriatric population, high sodium and low potassium intake, rising cases of obesity, increasing alcohol consumption in low- and middle-income countries, physical inactivity, and the lack of a balanced diet.
  • Additionally, increasing the patient pool of other chronic diseases like obesity among children and adults will power renal denervation market growth through the forecast period. As per the WHO's statistics, over 39 million children aged below 5 years were overweight in 2021. This condition is likely to push the demand for renal nerve denervation therapy, as high leptin levels in obese people can trigger the growth of blood vessels in the hypothalamus, thereby causing hypertension. A rise in the level of daily alcohol consumption will further drive the market growth, as regular drinking may lead to hypertension as it is possible that alcohol may stimulate adrenals to release adrenaline, resulting in increased heart rate, cardiac output, and systolic blood pressure.
  • Furthermore, an increase in clinical studies and research and development associated with renal denervation devices and the long-term benefits of renal denervation procedures are anticipated to drive market growth. For instance, as per the article published in April 2022 in Nature journal, more than 80% of Thai patients with resistant hypertension experienced the success of the renal nerve denervation outcome, which was sustained over a longer follow-up without any intervention-related side effects.
  • Hence, due to the rise in the prevalence of hypertension and the long-term benefits offered by renal denervation devices, the studied market is anticipated to witness growth in the studied market over the forecast period. However, stringent approval processes for renal denervation devices and reimbursement systems and painful procedures are anticipated to restrain the market growth over the forecast period.

Renal Denervation Devices Market Trends

The Ultrasound-based Segment is Expected to be the Fastest-growing Segment Over the Forecast Period

The ultrasound-based renal denervation devices are a minimally invasive procedure that uses ultrasound to ablate nerves in the wall of the renal arteries. It disrupts the transmission of nerve impulses to and from the kidney and lowers blood pressure. The ultrasound-based renal denervation devices are anticipated to witness growth in the market owing to the factors such as a rise in the prevalence of hypertension and an increase in demand for ultrasound-based renal denervation devices. For instance, as per the June 2022 update from WHO, it is estimated that at least one in four adults in India has hypertension, and only about 12% of them have their blood pressure under control. Such high blood pressure is linked with high cholesterol levels, and its growing incidence could bolster product demand for ultrasound-based renal denervation devices.

Furthermore, a rise in research studies of ultrasound-based renal denervation devices is anticipated to boost market growth over the forecast period. For instance, as per an article published in October 2021 by PubMed, an ultrasound In REsistant hypertension (REQUIRE) trial was designed to assess the BP-lowering efficacy of renal denervation in patients with resistant hypertension from Japan and South Korea. Thus, postive outcome of such studies may results into new treatment option, thereby increasing the segmental growth over the forecast period.

Innovative product launches and collaborations are some of the initiatives being undertaken in this segment by key market players to reinforce their presence in the global market. For instance, in December 2020, ReCor Medical Inc. received the US FDA's Breakthrough Device Designation for its innovative Paradise Ultrasound Renal Denervation System, designed to ablate the renal nerve using ultrasound energy. Hence, due to the rise in the prevalence of hypertension, the increase in research activities associated with ultrasound-based renal denervation devices and rise in product approvals, the studied segment is anticipated to witness growth in the market over the forecast period.

Europe is Anticipated to Witness a Significant Growth in the Renal Denervation Devices Market Over the Forecast Period

Europe is likely to witness significant growth in the renal denervation devices market owing to the factors such as a rise in the prevalence of hypertension, an increase in technological advancements, and the long-lasting effect of the procedure. For instance, as per the Office of Health Improvement and Disparities statistics, the prevalence of hypertension in England was 8,457,600 in 2021. Moreover, as per a Survey conducted in 2021 in Italy, 73.6% of participants reported being aware of their BP status, 42.3% reported a diagnosis of hypertension, and 41.4% were taking antihypertensive medications. The prevalence of self-reported hypertension was also greater in men than women. Thus, increasing the incidence of hypertension is one of the key factors responsible for the region's growth.

Furthermore, the major factor driving the market's growth is growing R&D activities to develop efficient devices. The rise in the number of product launches in the region will also contribute to the market's growth. For instance, in October 2021, ReCor Medical Inc. launched the ultrasound renal denervation system in Europe, which is likely to be used to treat uncontrolled hypertension in Germany. Hence, due to the rise in the prevalence of hypertension and the increase in product approvals for renal denervation devices, Europe is anticipated to witness growth over the forecast period.

Renal Denervation Devices Market Competitor Analysis

The market is consolidated due to the presence of some major market players. Various strategies, such as R&D, M&A, and product launch, are being adopted by key companies to strengthen their market position.

Some of the market players are Abbott, Ablative Solutions, Boston Scientific Corporation, CardioSonic, Kona Medical, Medtronic PLC, Mercator MedSystems, ReCor Medical, and Symple Surgical.

Additional Benefits:

  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 Study Assumptions and Market Definition
  • 1.2 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Rising Prevalence of Hypertension
    • 4.2.2 Long Lasting Effect of the Procedure
  • 4.3 Market Restraints
    • 4.3.1 Painful Procedure
    • 4.3.2 Stringent Approval Process for Renal Denervation Devices and Reimbursement Systems
  • 4.4 Porter's Five Forces Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION (Market Size by Value - USD million)

  • 5.1 By Technology
    • 5.1.1 Radiofrequency-based
    • 5.1.2 Ultrasound-based
    • 5.1.3 Micro-infusion-based
  • 5.2 Geography
    • 5.2.1 North America
      • 5.2.1.1 United States
      • 5.2.1.2 Canada
      • 5.2.1.3 Mexico
    • 5.2.2 Europe
      • 5.2.2.1 Germany
      • 5.2.2.2 United Kingdom
      • 5.2.2.3 France
      • 5.2.2.4 Italy
      • 5.2.2.5 Spain
      • 5.2.2.6 Rest of Europe
    • 5.2.3 Asia-Pacific
      • 5.2.3.1 China
      • 5.2.3.2 Japan
      • 5.2.3.3 India
      • 5.2.3.4 Australia
      • 5.2.3.5 South Korea
      • 5.2.3.6 Rest of Asia-Pacific
    • 5.2.4 Rest of the World

6 COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 Medtronic PLC
    • 6.1.2 Abbott Laboratories (St. Jude Medical Inc.)
    • 6.1.3 Otsuka Holdings Co. Ltd (ReCor Medical Inc.)
    • 6.1.4 Ablative Solutions Inc.
    • 6.1.5 Mercator MedSystems
    • 6.1.6 Terumo Corporation
    • 6.1.7 Symple Surgical
    • 6.1.8 Boston Scientific Corporation
    • 6.1.9 SoniVie
    • 6.1.10 Recor Medical Inc.

7 MARKET OPPORTUNITIES AND FUTURE TRENDS